The Global Diabetic Ketoacidosis Market reached US$ 1.5 billion in 2022 and is expected to reach US$ 2.3 billion by 2030 growing with a CAGR of 5.8% during the forecast period.
Diabetic Ketoacidosis Market Report by DataM Intelligence offers a detailed assessment of the global acute-care and diabetes management landscape, highlighting market size, key players, and critical growth drivers. With improvements in hospital DKA pathways, point-of-care testing, and integration of subcutaneous insulin strategies, the report delivers strategic insights for stakeholders from 2025 to 2033. In 2025, major guideline updates (ADA/ADA Standards of Care) clarified transitions from IV to subcutaneous insulin and refined DKA treatment pathways – changes that are already influencing hospital protocols and device/insulin delivery demand in the U.S. acute-care market.
The global diabetic ketoacidosis treatment market was valued at USD 3.6 billion in 2024 and is projected to grow from USD 3.8 billion in 2025 to USD 6.4 billion by 2034, registering a CAGR of 6.1% during the forecast period. This growth is primarily driven by the rising prevalence of diabetes, particularly type 1 diabetes, and the increasing adoption of advanced insulin delivery systems.
Innovations such as automated insulin pumps and continuous glucose monitoring (CGM) technologies are enhancing treatment precision and improving patient outcomes.
